У нас вы можете посмотреть бесплатно The impact of checkpoint inhibitor-based salvage regimens in patients with R/R HL undergoing autoSCT или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Sanjal Desai, MD, University of Minnesota Medical School, Minneapolis, MN, comments on the impact of checkpoint inhibitor-based salvage regimens in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (HL) undergoing autologous stem cell transplantation (autoSCT). Whilst there is no data on a head-to-head comparison of conventional chemotherapy with novel agents, retrospective data indicates that novel regimens incorporating nivolumab and brentuximab vedotin lead to a higher event-free survival (EFS) and a lower likelihood of progression before and after transplantation. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.